0H7R Stock Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Abeona Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.35 |
52 Week High | US$8.80 |
52 Week Low | US$2.76 |
Beta | 1.48 |
1 Month Change | -2.04% |
3 Month Change | 43.18% |
1 Year Change | 163.26% |
3 Year Change | -84.46% |
5 Year Change | n/a |
Change since IPO | -98.19% |
Recent News & Updates
Recent updates
Shareholder Returns
0H7R | GB Biotechs | GB Market | |
---|---|---|---|
7D | -2.2% | 1.7% | 2.2% |
1Y | 163.3% | -27.5% | 3.7% |
Return vs Industry: 0H7R exceeded the UK Biotechs industry which returned -27.5% over the past year.
Return vs Market: 0H7R exceeded the UK Market which returned 3.7% over the past year.
Price Volatility
0H7R volatility | |
---|---|
0H7R Average Weekly Movement | 14.2% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H7R's share price has been volatile over the past 3 months.
Volatility Over Time: 0H7R's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 84 | Vish Seshadri | https://www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
0H7R fundamental statistics | |
---|---|
Market cap | US$201.33m |
Earnings (TTM) | -US$54.19m |
Revenue (TTM) | US$3.50m |
57.5x
P/S Ratio-3.7x
P/E RatioIs 0H7R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0H7R income statement (TTM) | |
---|---|
Revenue | US$3.50m |
Cost of Revenue | US$2.69m |
Gross Profit | US$810.00k |
Other Expenses | US$55.00m |
Earnings | -US$54.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.98 |
Gross Margin | 23.14% |
Net Profit Margin | -1,548.23% |
Debt/Equity Ratio | 0% |
How did 0H7R perform over the long term?
See historical performance and comparison